Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.64 |
| ▸ | PGR | P06401 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL6 | P05231 | 1/20 | 0.64 |
| ▸ | GLUL | P15104 | 1/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL40948 | 1.00 | HIF1A (0.64) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7096415 | 0.97 | HIF1A (0.63) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL2299293 | 0.94 | HIF1A (0.72) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL13270299 | 0.94 | HIF1A (0.72) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL1512721 | 0.94 | HIF1A (0.72) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL719929 | 0.93 | HIF1A (0.70) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL1237365 | 0.92 | NR3C1 (0.65) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL1929804 | 0.92 | NR3C1 (0.64) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7600416 | 0.91 | HIF1A (0.66) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL5501494 | 0.91 | NR3C1 (0.67) | HIF1ANR3C1HSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119405590-A | Oral hydrogel for esophageal mucosa drug delivery and preparation method and application thereof | 四川大学 | 2025-02-11 | — | — | CN | claimed |
| CN-117425489-A | Composition for ex vivo organ care | 辛克利诺公司 | 2024-01-19 | — | — | CN | claimed |
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-116782865-A | Atomic layer deposition coated pharmaceutical packages, improved syringes and vials, e.g., for lyophilization/cold chain drugs/vaccines | SIO2医药产品公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | claimed |
| CN-116348093-A | Pharmaceutical composition of intra-articular corticosteroid for pain control | TLC生物医药公司 | 2023-06-27 | — | — | CN | claimed |
| EP-4748393-A1 | METHOD FOR TREATING ANCA-ASSOCIATED VASCULITIS USING TACI-FC FUSION PROTEIN | RemeGen Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| CN-119707932-A | Ethanesulfonic acid salts of quinoline derivatives | 小野药品工业株式会社 | 2025-03-28 | — | — | CN | disclosed |
| CN-117980333-A | Methods of treating chronic obstructive pulmonary disease with ST2 antagonists | 基因泰克公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-111902146-B | Medicinal products for treating cough | 日本化学药品株式会社 | 2024-04-12 | — | — | CN | disclosed |
| CN-117500807-A | Pyrrolopyrimidine compounds and use of pharmaceutical compositions thereof for the treatment of chronic graft versus host disease | 正大天晴药业集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117425489-A | Composition for ex vivo organ care | 辛克利诺公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1424335-A1 | INDOLE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1421934-A1 | REMEDIAL AGENT FOR ARTHROSIS DEFORMANS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-20030055039-A1 | Tnf-alpha inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-03-20 | — | — | US | disclosed |
| EP-1262180-A1 | TNF-ALPHA INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | HIF1A 2349/4885NR3C1 290/4885HSD17B10 151/4885 |
| US-20030055039-A1 | Tnf-alpha inhibitors | TNF, NFKBIA, TNFRSF1A | HIF1A 526/4885NR3C1 683/4885HSD17B10 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.